אפשרויות חיפוש:
"caso open" » "case open" (הרחבת חיפוש), "caso lopez" (הרחבת חיפוש), "cases open" (הרחבת חיפוש)
"esto open" » "tests open" (הרחבת חיפוש), "esto en" (הרחבת חיפוש), "nest open" (הרחבת חיפוש)
"oto open" » "two open" (הרחבת חיפוש)
"eo open" » "neo open" (הרחבת חיפוש), "do open" (הרחבת חיפוש), "ao open" (הרחבת חיפוש)
"esmo open" » "eso open" (הרחבת חיפוש), "ecmo open" (הרחבת חיפוש)
A mostrar 1 - 20 resultados de 1,103 para a pesquisa '(((("eo open") OR ((("esmo open") OR ("esto open"))))) OR ((("oto open") OR ("caso open"))))', זמן שאילתה: 1.36seg Refinar resultados
Presenting OTO Open
AIOM chooses ESMO Open—Cancer Horizons as its official journal: a warm welcome from ESMO Open

ESMO Open—Cancer Horizons and the future of oncology
CSCO joins ESMO Open—Cancer Horizons

ESMO Open: news in breast cancer 2019
ESMO Open welcomes the association with the Japanese Society of Medical Oncology (JSMO)

ESMO Open special series on new emerging targets in cancer immunotherapy
Announcing the ESMO Open special issue on upcoming molecular targets for cancer treatment

One year of ESMO Open: Cancer Horizons—where are we going from here?
Introducing a new ESMO Open article series: how I treat side effects of immunotherapy

Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open–Cancer Horizons roundtable discussion
First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion

CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open—Cancer Horizons pro and con discussion
EDUCAÇÃO A DISTÂNCIA: O CASO OPEN UNIVERSITY

New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an “ESMO Open – Cancer Horizons” Series
Erratum to ‘FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?’: [ESMO Open Volume 5, Issue 5, 2020, e000633]

Erratum to ‘Adjuvant endocrine therapy in HER2-positive breast cancer patients: systematic review and meta-analysis’: [ESMO Open Volume 6, Issue 2, April 2021, 100088]
Corrigendum to ‘Clinical significance of ERBB2 exon 16 skipping: analysis of a real-world retrospective observational cohort study’: [ESMO Open Volume 5, Issue 6, 2020, e000985]

Erratum to ‘Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome’: [ESMO Open Volume 6, Issue 1, February 2021, 100005]
Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’: [ESMO Open Volume 6, Issue 2, April 2021, 100078]

כלי חיפוש: קבל רסס (RSS) — שליחת חיפוש דרך דואל — שמירת חיפוש